Vividion Names Receptos Alum Fred Aslan President

San Diego biotech Vividion Therapeutics, which says it is deploying proteomics and chemistry platforms to discover and develop novel small-molecule therapeutics, announced on Tuesday it has appointed Fred Aslan as its president and chief business officer. Aslan was a co-founder of Receptos Pharmaceuticals, which was acquired by Celgene for about $7 billion in 2015. Most recently Aslan was founder and CEO of Adavium Medical, a Brazilian medical device company; before that he was an investor at venture capital firm Venrock. Vividion, headed by CEO Diego Miralles, was spun out of the Scripps Research Institute in La Jolla.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.